The targeting of metabolic plasticity by aspirin exposes metabolic vulnerabilities and provides an exciting opportunity for the use of aspirin in combination with specific metabolic inhibitors (including GLS inhibitors such as CB839 and IACS-6274, currently in clinical trials) for the treatment of CRC and potentially other cancers. This evidence concerns the gene GLS and cancer.